JP2003532618A - 細胞、神経系−特異的抗原およびそれらの用途 - Google Patents
細胞、神経系−特異的抗原およびそれらの用途Info
- Publication number
- JP2003532618A JP2003532618A JP2000549639A JP2000549639A JP2003532618A JP 2003532618 A JP2003532618 A JP 2003532618A JP 2000549639 A JP2000549639 A JP 2000549639A JP 2000549639 A JP2000549639 A JP 2000549639A JP 2003532618 A JP2003532618 A JP 2003532618A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- injury
- mbp
- specific
- rats
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12455098A IL124550A0 (en) | 1997-07-21 | 1998-05-19 | Compositions comprising activated t-cells or t-cell activating agents and their use |
| IL124550 | 1998-05-19 | ||
| US9814715 | 1998-07-21 | ||
| PCT/US1998/014715 WO1999034827A1 (en) | 1998-07-21 | 1998-07-21 | Activated t-cells and their uses |
| US09/218,277 | 1998-12-22 | ||
| US09/218,277 US20030108528A1 (en) | 1998-05-19 | 1998-12-22 | Activated t-cells, nervous system-specific antigens and their uses |
| PCT/US1999/010953 WO1999060021A2 (en) | 1998-05-19 | 1999-05-19 | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003532618A true JP2003532618A (ja) | 2003-11-05 |
| JP2003532618A5 JP2003532618A5 (cg-RX-API-DMAC7.html) | 2006-08-03 |
Family
ID=27271868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000549639A Abandoned JP2003532618A (ja) | 1998-05-19 | 1999-05-19 | 細胞、神経系−特異的抗原およびそれらの用途 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1080110A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003532618A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2328612A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999060021A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0866805A1 (en) | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US20020072493A1 (en) * | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US7060670B1 (en) | 1999-05-05 | 2006-06-13 | Neurochem (International) Limited | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7351686B2 (en) | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| EP2892353A4 (en) | 2012-09-10 | 2016-10-26 | Yeda Res & Dev | INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991001746A1 (en) * | 1989-08-09 | 1991-02-21 | The Children's Medical Center Corporation | Thy-1 receptor and its use for regenerating nerve cell processes |
| DE69331501T2 (de) * | 1992-04-09 | 2002-08-29 | Autoimmune, Inc. | Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin |
| GB9403250D0 (en) * | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
| CA2187345A1 (en) * | 1994-04-08 | 1995-10-19 | Howard L. Weiner | Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines |
| CZ122697A3 (en) * | 1994-10-25 | 1997-09-17 | Immulogic Pharma Corp | Preparations and methods of treating disseminated sclerosis |
| US5932542A (en) * | 1995-06-27 | 1999-08-03 | Research Foundation Of Cuny, Hunter College | Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof |
| US5800812A (en) * | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
| SE505316C2 (sv) * | 1995-10-17 | 1997-08-04 | Kenneth G Haglid | Användning av proteinet S-100b för framställning av läkemedel för nervceller |
| AU5671196A (en) * | 1996-03-28 | 1997-10-17 | Immulogic Pharmaceutical Corporation | Myelin oligodendrocyte glycoprotein peptides and uses thereof |
| SE9703287D0 (sv) * | 1997-09-11 | 1997-09-11 | Astra Ab | Peptides |
| WO1999053945A1 (en) * | 1998-04-16 | 1999-10-28 | Samuel David | Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration |
-
1999
- 1999-05-19 WO PCT/US1999/010953 patent/WO1999060021A2/en not_active Ceased
- 1999-05-19 CA CA002328612A patent/CA2328612A1/en not_active Abandoned
- 1999-05-19 EP EP99923190A patent/EP1080110A2/en not_active Withdrawn
- 1999-05-19 JP JP2000549639A patent/JP2003532618A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999060021A2 (en) | 1999-11-25 |
| EP1080110A2 (en) | 2001-03-07 |
| WO1999060021A3 (en) | 2000-06-15 |
| CA2328612A1 (en) | 1999-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60116467T2 (de) | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat | |
| DE60112718T2 (de) | Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie | |
| US7560102B2 (en) | Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease | |
| WO1999060021A2 (en) | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system | |
| KR20040032825A (ko) | 신경보호 치료를 위한 폴리-glu,tyr, 및 이로처리된 t 세포의 용도 | |
| AU2002345323A1 (en) | Use of poly-Glu, Tyr for neuroprotective therapy | |
| JP2006503808A (ja) | 神経保護及び神経再生用の抗原提示細胞 | |
| US7399740B2 (en) | Poly-Glu,Tyr for neuroprotective therapy | |
| JP2002500199A (ja) | 活性化t細胞、及びそれらの用途 | |
| WO2005044298A1 (en) | Compositions and methods of treatment | |
| AU768763B2 (en) | Activated T cells, nervous system-specific antigens and their uses | |
| MXPA00011385A (en) | Activated t cells, nervous system-specific antigens and their uses | |
| AU755872B2 (en) | Activated T-cells and their uses | |
| HK1058892B (en) | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith in protecting cns cells from glutamate toxicity | |
| MXPA00000840A (en) | Activated t-cells and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060516 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060609 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20070709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070905 |